Arvinas, in collaboration with Pfizer, has announced vepdegestrant NDA acceptance by the FDA for breast cancer treatment.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.